{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T18:15:06Z","timestamp":1794075306493,"version":"4.8.0"},"reference-count":32,"publisher":"BMJ","issue":"11","funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["ML29875"],"award-info":[{"award-number":["ML29875"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2023,3,18]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Fibrotic hypersensitivity pneumonitis (FHP) is an irreversible lung disease with high morbidity and mortality. We sought to evaluate the safety and effect of pirfenidone on disease progression in such patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a single-centre, randomised, double-blinded, placebo-controlled trial in adults with FHP and disease progression. Patients were assigned in a 2:1 ratio to receive either oral pirfenidone (2403 mg\/day) or placebo for 52 weeks. The primary end point was the mean absolute change in the per cent predicted forced vital capacity (FVC%). Secondary end points included progression-free survival (PFS, time to a relative decline \u226510% in FVC and\/or diffusing capacity of the lung for carbon monoxide (DLCO), acute respiratory exacerbation, a decrease of \u226550 m in the 6 min walk distance, increase or introduction of immunosuppressive drugs or death), change in FVC slope and mean DLCO%, hospitalisations, radiological progression of lung fibrosis and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After randomising 40 patients, enrolment was interrupted by the COVID-19 pandemic. There was no significant between-group difference in FVC% at week 52 (mean difference \u22120.76%, 95% CI \u22126.34 to 4.82). Pirfenidone resulted in a lower rate of decline in the adjusted FVC% at week 26 and improved PFS (HR 0.26, 95% CI 0.12 to 0.60). Results for other secondary end points showed no significant difference between groups. No deaths occurred in the pirfenidone group and one death (respiratory) occurred in the placebo group. There were no treatment-emergent serious adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The trial was underpowered to detect a difference in the primary end point. Pirfenidone was found to be safe and improved PFS in patients with FHP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration mumber<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02958917\">NCT02958917<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/thorax-2022-219795","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T17:20:35Z","timestamp":1680888035000},"page":"1097-1104","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":47,"title":["Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety"],"prefix":"10.1136","volume":"78","clinical-trial-number":[{"clinical-trial-number":"nct02958917","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02958917","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-1591","authenticated-orcid":false,"given":"Evans R","family":"Fern\u00e1ndez P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0021-5701","authenticated-orcid":false,"given":"James L","family":"Crooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6329-2325","authenticated-orcid":false,"given":"David A","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5113-4530","authenticated-orcid":false,"given":"Stephen M","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman L","family":"Koelsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2643-8110","authenticated-orcid":false,"given":"Jeffrey J","family":"Swigris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-4874","authenticated-orcid":false,"given":"Joshua J","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Mohning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve D","family":"Groshong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Fier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"2024051320410376000_78.11.1097.1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201704-288OC"},{"key":"2024051320410376000_78.11.1097.2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2623"},{"key":"2024051320410376000_78.11.1097.3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s13665-014-0094-0","article-title":"Fibrotic hypersensitivity pneumonitis","volume":"3","author":"Fern\u00e1ndez P\u00e9rez","year":"2014","journal-title":"Curr Respir Care Rep"},{"key":"2024051320410376000_78.11.1097.4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1164\/rccm.201807-1258LE","article-title":"Increasing hypersensitivity pneumonitis-related mortality in the United States from 1988 to 2016","volume":"199","author":"Fern\u00e1ndez P\u00e9rez","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024051320410376000_78.11.1097.5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2685"},{"key":"2024051320410376000_78.11.1097.6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00085-2020","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"55","author":"Brown","year":"2020","journal-title":"Eur Respir J"},{"key":"2024051320410376000_78.11.1097.7","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001111"},{"key":"2024051320410376000_78.11.1097.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2024051320410376000_78.11.1097.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2024051320410376000_78.11.1097.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00005209"},{"key":"2024051320410376000_78.11.1097.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-571OC"},{"key":"2024051320410376000_78.11.1097.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217693"},{"key":"2024051320410376000_78.11.1097.13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S2213-2600(17)30216-3","article-title":"The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study","volume":"5","author":"Ley","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024051320410376000_78.11.1097.14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024051320410376000_78.11.1097.15","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez P\u00e9rez ER , Crooks JL , Swigris JJ , et al . Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis. ERJ Open Res 2021;7. doi:10.1183\/23120541.00054-2021","DOI":"10.1183\/23120541.00054-2021"},{"key":"2024051320410376000_78.11.1097.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2024051320410376000_78.11.1097.17","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2462070712"},{"key":"2024051320410376000_78.11.1097.18","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000091"},{"key":"2024051320410376000_78.11.1097.19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.3.619"},{"key":"2024051320410376000_78.11.1097.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(06)80166-6"},{"key":"2024051320410376000_78.11.1097.21","doi-asserted-by":"crossref","unstructured":"Swigris J , Cutts K , Male N , et al . The living with pulmonary fibrosis questionnaire in progressive fibrosing interstitial lung disease. ERJ Open Res 2021;7. doi:10.1183\/23120541.00145-2020","DOI":"10.1183\/23120541.00145-2020"},{"key":"2024051320410376000_78.11.1097.22","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01384-2018","article-title":"Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis","volume":"52","author":"Humphries","year":"2018","journal-title":"Eur Respir J"},{"key":"2024051320410376000_78.11.1097.23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1148\/radiol.2017161177","article-title":"Idiopathic pulmonary fibrosis: data-driven textural analysis of extent of fibrosis at baseline and 15-month follow-up","volume":"285","author":"Humphries","year":"2017","journal-title":"Radiology"},{"key":"2024051320410376000_78.11.1097.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6973.170"},{"key":"2024051320410376000_78.11.1097.25","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.329"},{"key":"2024051320410376000_78.11.1097.26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (relief): a double-blind, randomised, placebo-controlled, phase 2B trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024051320410376000_78.11.1097.27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024051320410376000_78.11.1097.28","unstructured":"Khanna D , Spino C , Bernstein E , et al . Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the scleroderma lung study III [abstract]. Arthritis Rheumatol 2022;74. Available: https:\/\/acrabstracts.org\/abstract\/combination-therapy-of-mycophenolate-mofetil-and-pirfenidone-vs-mycophenolate-alone-results-from-the-scleroderma-lung-study-iii\/"},{"key":"2024051320410376000_78.11.1097.29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024051320410376000_78.11.1097.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2024051320410376000_78.11.1097.31","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s12325-021-02009-w","article-title":"Pirfenidone in unclassifiable interstitial lung disease: a subgroup analysis by concomitant mycophenolate mofetil and\/or previous corticosteroid use","volume":"39","author":"Kreuter","year":"2022","journal-title":"Adv Ther"},{"key":"2024051320410376000_78.11.1097.32","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.chest.2021.03.066","article-title":"Diagnosis and evaluation of hypersensitivity pneumonitis: chest guideline and expert panel report","volume":"160","author":"Fern\u00e1ndez P\u00e9rez","year":"2021","journal-title":"Chest"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2022-219795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T03:55:57Z","timestamp":1715658957000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2022-219795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,10,17]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/thorax-2022-219795"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2022-219795","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]}}}